IMM vs. BVX, SAR, ROQ, GENF, BSFA, VAL, IXI, OCTP, SNG, and FAB
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include BiVictriX Therapeutics (BVX), Sareum (SAR), Roquefort Therapeutics (ROQ), Genflow Biosciences (GENF), BSF Enterprise (BSFA), ValiRx (VAL), IXICO (IXI), Oxford Cannabinoid Technologies (OCTP), Synairgen (SNG), and Fusion Antibodies (FAB). These companies are all part of the "biotechnology" industry.
ImmuPharma (LON:IMM) and BiVictriX Therapeutics (LON:BVX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking.
24.0% of ImmuPharma shares are owned by institutional investors. Comparatively, 34.8% of BiVictriX Therapeutics shares are owned by institutional investors. 43.0% of ImmuPharma shares are owned by insiders. Comparatively, 36.7% of BiVictriX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
ImmuPharma has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, BiVictriX Therapeutics has a beta of -0.6, indicating that its share price is 160% less volatile than the S&P 500.
In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled BiVictriX Therapeutics'average media sentiment score.
ImmuPharma received 266 more outperform votes than BiVictriX Therapeutics when rated by MarketBeat users.
BiVictriX Therapeutics has lower revenue, but higher earnings than ImmuPharma. BiVictriX Therapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
BiVictriX Therapeutics' return on equity of -59.06% beat ImmuPharma's return on equity.
Summary
ImmuPharma beats BiVictriX Therapeutics on 6 of the 10 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
